glp-1 agonist in esrd receptor agonists' impact on cardio-renal outcomes and mortality T2D with acute kidney disease GLP-1 Receptor Agonists and Diabetic

I created this visual guide to consolidate the landmark trials that have redefined our clinical guidelinesmapping the journey from the early cardiovascular outcome trials to the latest breakthroughs in obesity and renal protection

We can help you explore this uncharted territory and strategize for success

The choice of GLP-1 medication depends on individual factors, and patients are advised to discuss their options with healthcare providers to create personalized treatment plans that effectively manage their condition

The FDA Adverse Event Reporting System shows a likely link between GLP-1 RAs (specifically liraglutide) and increased risk of pancreatitis

Curr Med Res Opin 24(1):275286

Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 Randomized Clinical Trial